Velia | About Us

Timeline to Velia Build

2023

Michael York joins Velia as Chief Business Officer

2023

John McHutchison, AO, MD joins Velia as President and CEO.

2022

Velia formed!

2021

The Column Group and Foresite Capital begin assembling founder team.

2020

Chen et al found multiple microproteins encoded in upstream open reading frames and revealed the use of functional bicistronic operons in mammals (Science 2020).

2014

Ribosome profiling provides evidence that translation occurs outside of protein-coding genes. In Nat Rev Genet (2014) Ingolia detailed studies providing new insights into the identity and the amount of proteins that are produced by cells.

Mission Statement

Where most biotech companies find new approaches to drug known targets, Velia is uncovering novel biology.

Our mission is to harness the therapeutic potential of a newly identified, yet abundant class of human proteins. Our strategy is to discover and characterize disease-relevant proteins across the human proteome and generate first-in-class, transformative therapeutics. Our unique approach combines deep founder expertise in protein discovery, functional genomics, and AI to unveil important therapeutic nodes.